Spain · Delayed Price · Currency is EUR Faes Farma Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 27% year-over-year to EUR 391.5 million, with EBITDA up 24% and net income up 9%. Integration of SIFI and Edol boosted ophthalmology, now 16% of revenue. Guidance for 2026 reaffirmed, with strong international and LATAM growth expected.
-
Revenue grew 31% year-over-year to EUR 200.1 million, with strong organic and acquisition-driven growth. Net profit rose 9%, and guidance for 2026 is maintained despite expected headwinds from Bilastine generics in Japan.
Fiscal Year 2025
-
2025 saw 23% revenue growth, major acquisitions, and strong international expansion, with adjusted EBITDA up 3.1% and net profit down due to one-offs. 2026 guidance targets 17%-19% revenue and 28%-31% EBITDA growth, with continued focus on integration, efficiency, and international markets.
-
The acquisition of SIFI accelerates the 2030 growth strategy, expanding the ophthalmology portfolio, global reach, and R&D pipeline. The €270 million deal is expected to be EPS accretive from year one, with strong synergies, high-margin businesses, and limited competition in key areas.